Cell Therapeutics Backpedals Again, Pulls Pixantrone NDA
The cancer candidate pixantrone (Pixuvri) took another detour in its long and tortuous road to seek potential FDA approval as developer Cell Therapeutics Inc. voluntarily withdrew its new drug application (NDA) in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter